Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 with or without AK117 in metastatic colorectal cancer
NCT05382442Phase 2Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jun 2022
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of ivonescimab in metastatic colorectal cancer (mCRC) (11 arms), sponsored by Akeso, Inc. Primary endpoints: Objective Response Rate at 2 years and Adverse Events at 2 years. Started Jun 2022; status: active, not recruiting.
02
Drugs
ivonescimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05382442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382442.